Mirum Pharmaceuticals Plans to Offer $600M Convertible Senior Notes
Mirum Pharmaceuticals announced its intention to offer, subject to market conditions and other factors, $600M aggregate principal amount of convertible senior notes due 2032 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
